After analyzing stroke treatment records, researchers at Rhode Island Hospital in collaboration with researchers from the University of Cincinnati learned that women and men have different reasons for being excluded from receiving the common clot-dissolving drug, recombinant tissue plasminogen activator (rtPA). Importantly, more women had very high blood pressures, which reduced their eligibility to be treated with the highly effective drug. The study was recently published in the American Heart Association's (AHA) journal, Stroke.
↧